Angion Biomedica shares dive after kidney-disease drug trial discontinued
June 29, 2022 at 17:37 PM EDT
Angion Biomedica Corp. shares dived 30% to $1.20 in after-hours trading Wednesday after the company said it is discontinuing a Phase 2 trial of ANG-3070 in patients with primary proteinuric kidney diseases.
